ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers
Authors:
- 4 October 2023
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 51 (2) , 380-394
Abstract
Purpose The high expression of the transmembrane glycoprotein trophoblast cell-surface antigen 2 (Trop2) was strongly associated with the progression of solid tumors, including pancreatic and gastric cancers. Our study aimed to construct Trop2-specific immuno-positron emission tomography (immunoPET) probes and assess the diagnostic abilities in preclinical pancreatic and gastric cancer models. Methods The expression of Trop2 in pancreatic cancer was determined by single-cell sequencing and immunohistochemistry on tissue microarray (TMA). Flow cytometry was used to screen the expression of Trop2 in pancreatic cancer cell lines. Two nanobodies (i.e., RTD98 and RTD01) targeting Trop2 were developed and labeled with gallium-68 (68Ga, T1/2 = 1.1 h) to construct immunoPET imaging probes. The agents were researched in cell-derived pancreatic and patient-derived gastric cancer models expressing varying Trop2. Results Single-cell sequencing results showed high expression of Trop2 in pancreatic ductal cells as well as acinar cells and immunohistochemical staining of TMA from pancreatic cancers showed significantly higher expression of Trop2 in cancerous than in paracancerous tissues. ImmunoPET utilizing [68Ga]Ga-NOTA-RTD98 could clearly delineate subcutaneous tumors, both in cell-derived pancreatic cancer models and patient-derived gastric cancer models, superior to imaging using [18F]-FDG or a non-specific probe [68Ga]Ga-NOTA-RTD161. Another probe with improved pharmacokinetics targeting Trop2, [68Ga]Ga-NOTA-RTD01, was further prepared and showed advantageous diagnostic capabilities in preclinical pancreatic cancer models. Conclusion In the work, we reported two nanobody tracers targeting human Trop2 which may facilitate better use of Trop2-targeted therapeutics by noninvasively displaying expression dynamics of the target.Keywords
Funding Information
- National Key Research and Development Program of China (2021YFA0910000)
- National Natural Science Foundation of China (82372014, 82171972, 82001878)
This publication has 39 references indexed in Scilit:
- Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancerWorld Journal of Gastroenterology, 2014
- Therapeutic antibodies: successes, limitations and hopes for the futureBritish Journal of Pharmacology, 2009
- TROP2 expression as prognostic marker for gastric carcinomaJournal of Clinical Pathology, 2008
- High expression of TROP2 correlates with poor prognosis in pancreatic cancerBritish Journal of Cancer, 2008
- Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancersMolecular Cancer Therapeutics, 2008
- Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapyApplied Microbiology and Biotechnology, 2006
- Cloning of the gene encoding TROP‐2, a cell‐surface glycoprotein expressed by human carcinomasInternational Journal of Cancer, 1995
- Characterization of cluster 13: The epithelial/carcinoma antigen recognized by MAb RS7International Journal of Cancer, 1994
- Specificity and properties of MAb RS7‐3G11 and the antigen defined by this pancarcinoma monoclonal antibodyInternational Journal of Cancer, 1993
- Human trophoblast cell-surface antigens defined by monoclonal antibodies.Proceedings of the National Academy of Sciences, 1981